Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 7,866 matching trials from the live ClinicalTrials.gov search.

Filters: Minneapolis, Minnesota Clear all

Conditions: Pancreatic Cancer
Interventions: Gemcitabine, radiation therapy; Drug · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 228
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Fresno, California + 164 more

Conditions: Lung Cancer
Interventions: carboplatin, gefitinib, paclitaxel; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 65 Years to 120 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 140
States / cities: Scottsdale, Arizona • Fort Collins, Colorado • Jacksonville, Florida + 88 more

Conditions: Heart Failure
Interventions: Finerenone, Empagliflozin; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 46
States / cities: Fairhope, Alabama • Phoenix, Arizona • Chula Vista, California + 40 more

Conditions: Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
Interventions: Anti TNF therapy including infliximab, No Biologics; Biological · Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 4,970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2038
U.S. locations: 58
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more

Conditions: Smoking Cessation
Interventions: NicVAX vaccine, Placebo; Biological
Lead sponsor: Nabi Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 25
States / cities: Tucson, Arizona • Encino, California • Los Alamitos, California + 21 more

Conditions: Depressive Disorder, Bipolar Disorder, Suicide, Suicide, Attempted
Interventions: Lithium, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 28
States / cities: Phoenix, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 25 more

Conditions: Pulmonary Hypertension
Interventions: tadalafil, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 3
States / cities: Tucson, Arizona • Minneapolis, Minnesota • Salt Lake City, Utah

Conditions: Follicular Lymphoma
Interventions: AT-101, Rituximab; Drug
Lead sponsor: Ascenta Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 25 more

Conditions: Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial, Major Bleeding
Interventions: Home Monitoring Guided OAC, Physician-Directed OAC; Drug
Lead sponsor: Biotronik, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 73
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 70 more

Conditions: Stickler Syndrome Type 1, Stickler Syndrome Type 2
Interventions: Prophylactic (non-invasive) Laser Retinopexy; Procedure
Lead sponsor: Helen Keller Eye Research Foundation; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 6
States / cities: Birmingham, Alabama • Boston, Massachusetts • Royal Oak, Michigan + 3 more

Conditions: Glioblastoma
Interventions: enzastaurin, lomustine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 42
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 39 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Ataluren; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 2 Years to 7 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 6 more

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: lomustine, temozolomide; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Paravalvular Aortic Regurgitation
Interventions: AVP III; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 14
States / cities: Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 10 more

Conditions: Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Salivary Duct Carcinoma, Salivary Gland Adenocarcinoma, NOS, Salivary Gland Basal Cell Adenocarcinoma, Stage III Major Salivary Gland Cancer AJCC v7
Interventions: enzalutamide; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 287
States / cities: Anchorage, Alaska • Anaheim, California • Baldwin Park, California + 201 more

Conditions: Anorexia, Generalized Anxiety
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Post Traumatic Stress Disorder
Interventions: Partnered Prolonged Exposure (PPE), Prolonged Exposure (PE); Behavioral
Lead sponsor: United States Department of Defense; Federal
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Phoenix, Arizona • San Diego, California • Minneapolis, Minnesota + 1 more

Conditions: Colorectal Cancer
Interventions: bevacizumab, cetuximab, FOLFOX or, FOLFIRI; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 2,334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 662
States / cities: Mobile, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 468 more

Conditions: Squamous Non-Small Cell Lung Cancer
Interventions: Carboplatin, Veliparib, Paclitaxel, Placebo to veliparib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 38
States / cities: Jonesboro, Arkansas • Los Angeles, California • Aurora, Colorado + 30 more

Conditions: Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Interventions: Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine); Drug
Lead sponsor: GRADE Study Group; Other
Eligibility: 30 Years and older
Enrollment: 7,850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 28 more

Conditions: Chronic Pain
Interventions: MagVenture X100 Pro transcranial magnetic stimulation system; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions: Extended release niacin, Simvastatin; Drug
Lead sponsor: Axio Research. LLC; Industry
Eligibility: 45 Years and older
Enrollment: 3,414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 68
States / cities: Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more

Conditions: COPD
Interventions: Placebo, EP-101 12.5 mcg, EP-101 25 mcg, EP-101 50 mcg, EP-101 100 mcg; Drug
Lead sponsor: Sunovion Respiratory Development Inc.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 26
States / cities: Jasper, Alabama • Phoenix, Arizona • Fullerton, California + 21 more

Conditions: Congenital Cataract
Interventions: Contact lens correction of aphakia, Intraocular lens implantation; Device
Lead sponsor: Stanford University; Other
Eligibility: 28 Days to 210 Days
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2020
U.S. locations: 13
States / cities: Palo Alto, California • Miami, Florida • Atlanta, Georgia + 10 more

Search by objective public record fields.

Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

Lithium for Suicidal Behavior in Mood Disorders

PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS)

Enzastaurin Versus Lomustine in Glioblastoma

A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma

PARADIGM: Amplatzer Valvular Plug for PVL Closure

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

Overgeneralization of Conditioned Fear as a Pathogenic Marker of Anorexia Nervosa

A Hybrid 1 Effectiveness-Implementation Trial of Partner-Assisted Prolonged Exposure for PTSD

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Optimizing Accelerated TMS for Chronic Pain With Thompson Sampling

Niacin Plus Statin to Prevent Vascular Events

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

Infant Aphakia Treatment Study (IATS)